Impact of magnesium on the clearance of lactate in critically sick patients with sepsis: Randomized clinical trial

Table 1 Comparison of demographic parameters, n (%)/median (range)

Parameter	Group M (n = 69)	Group P (n = 69)	P value
Age (years)	54.00 (18-93)	42.00 (19-84)	0.1221
Gender
Male	44 (63.77)	43 (62.31)	0.8602
Female	25 (36.23)	26 (37.68)
Weight (kg)	68.00 (48-92)	68.00 (48-90)	0.9521
Comorbidities
Hypertension	25 (36.23)	24 (34.78)	0.8592
Diabetes	24 (34.78)	18 (26.09)	0.2672
Chronic lung disease	04 (5.79)	05 (7.24)	0.7302
Cerebrovascular disease	08 (11.59)	05 (7.24)	0.3822
Cause of ICU admission
Surgical	34 (49.28)	32 (46.38)	0.1162
Medical	35 (50.72)	37 (53.62)
Source of sepsis
Lung
CAP	11 (15.94)	13 (18.84)
VAP	10 (14.49)	11 (15.94)
ARDS	5 (7.24)	3 (4.34)
Lung abscess	1 (1.44)	2 (2.89)
Abdomen
Peritonitis	13 (18.84)	11 (15.94)
Urinary tract infection	9 (13.04)	11 (15.94)
Pancreatitis	3 (4.34)	2 (2.89)
Liver abscess	2 (2.89)	1 (1.44)
Blood
Candidemia	2 (2.89)	3 (4.34)
Brain/CNS
Meningitis	3 (4.34)	4 (5.79)
Pots spine	2 (2.89)	1 (1.44)
Encephalitis	2 (2.89)	1 (1.44)
Skin and soft tissue
Soft tissue	2 (2.89)	1 (1.44)
Gluteal abscess	1 (1.44)	2 (2.89)
Necrotizing fasciitis	2 (2.89)	1 (1.44)
Pectoral abscess	1 (1.44)	2 (2.89)

¹Mann-Whitney U test.

²χ² test.

M: Magnesium group; P: Placebo group; ICU: Intensive care unit; CAP: Community-acquired pneumonia; VAP: Ventilator-associated pneumonia; ARDS: Acute respiratory distress syndrome; CNS: Central nervous system.